The feasibility of modified directly observed therapy for HIV-seropositive African American substance users

AIDS Patient Care and STDs

Volumn 22, Issue 2, 2008, Pages 139-146

  Ma, Mindy ^a,e   Brown, Billy R ^b   Coleman, Melissa ^c   Kibler, Jeffrey L ^a   Loewenthal, Helen ^d   Mitty, Jennifer A ^d  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b GV (Sonny) Montgomery Veterans Administration Medical Center   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e JACKSON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DEPRESSION; DIRECTLY OBSERVED THERAPY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PATIENT COMPLIANCE; RISK ASSESSMENT; SUBSTANCE ABUSE; VIRUS LOAD;

ADULT; AFRICAN AMERICANS; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 39149087984     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0063     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. HIV/AIDS among African Americans. CDC HIV/AIDS Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention, 2007. www.cdc.gov/hiv/topics/aa/resources/factsheets/pdf/aa.pdf. (Last accessed May 3, 2007).
2. Centers for Disease Control and Prevention. HIV/ AIDS Surveillance Report 2004. MMWR 2005;16:1-46.
3. Kaiser Family Foundation. The Black Americans and HIV/AIDS. HIV/AIDS Policy Fact Sheet. Menlo Park, CA: 2006. www.kff.org. (Last accessed April 15, 2007).
4. Butcher RO, Hood RG, Jordan, WC. Optimizing treatment for African American and Latinos with HIV/AIDS. J Natl Med Assoc 2005;97:1093-1100.
5. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-381.
6. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002;46:93-108.
7. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-259.
8. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health 2004;29:117-127.
9. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-756.
10. Williams M, Bowen A, Ross M, Freeman R, Elwood W. Perceived compliance with AZT dosing among a sample of African-American drug users. Int J STD AIDS 2000;11:57-63.
11. Behforouz HL, Former PE, Mukherjee JS. From directly observed therapy to accompagnateur: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38:S429-S436.
12. Mitty JA, Macalino G, Bazerman L, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005;39:545-550.
13. Stenzel M S, McKenzie M, Mitty JA, Flanigan TP. Enhancing adherence to HAART: A pilot program of modified directly observed therapy. AIDS Read 2001;11:317-328.
14. Wohl AR, Garland WH, Squires K, et al. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis 2004;38:S388-S392.
15. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIVinfected drug users: Implications for program replication. Clin Infect Dis 2004;38:S376-S387.
16. Macalino GE, Mitty JA, Bazerman LB, Singh K, McKenzie M, Flanigan T. Modified directly observed therapy for the treatment of HIVseropositive substance users: Lessons learned from a pilot study. Clin Infect Dis 2004;38:S393-S397.
17. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002;1:271-280.
18. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004;38:S402-408.
19. Macalino GE, Hogan J, Mitty JA, et al. A randomized clinical trial of community based directly observed therapy (MDOT) as an adherence intervention for highly active antiretroviral therapy (HAART) among substance users. AIDS (in press).
20. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006;42:1628-1635.
21. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDs 2002;16:527-535.
22. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clin Infect Dis 2002;34:984-990.
23. Kagay CR, Porco TC, Liechty CA, et al. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis 2004;38:S414-S420.
24. Jordan WC, Vaughn AC, Hood RG. African Americans and HIV/AIDS: cultural concerns. AIDS Read 2004;14:S22-S25.
25. Lee-Ougo W, Boekeloo BO, Thompson EE, et al. Provider perceptions of key barriers to providing state-of-the-art clinical care for HIV-infected African-American patients. J Natl Med Assoc 2003;95:S12-S20.
26. Whetten K, Reif S. Overview: HIV/AIDS in the Deep South region of the United States. AIDS Care 2006;18:S1-S5.
27. Bogart LM, Bird ST. Exploring the relationship of conspiracy beliefs about HIV/AIDS to sexual behaviors and attitudes among African-American adults. J Natl Med Assoc 2003;95:1057-1065.
28. Bogart LM, Thorburn S. Relationship of African Americans' sociodemographic characteristics to belief in conspiracies about HIV/AIDS and birth control. J Natl Med Assoc 2006;98:1144-1150.
29. Guinan ME. Black communities' belief in "AIDS as genocide." A barrier to overcome for HIV prevention. Ann Epidemiol 1993;3:193-195.
30. Bogart LM, Thorburn, S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr 2005;38:213-218.
31. Kaiser Family Foundation. The HIV/AIDS epidemic in the United States. HIV/AIDS Policy Fact Sheet. Menlo Park, CA: 2006. www.kff.org. (Last accessed April 15, 2007).
32. Kaiser Family Foundation. Mississippi Living HIV Disease Report. Menlo Park, CA: 2005. Available at: www.statehealthfacts.org. (Last accessed April 15, 2007).
33. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-1907.
34. Beck AT, Steer RA, Brown, GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.
35. Lucas GM, Weidle PJ, Hader, S, Moore RD. Directly administered antiretroviral therapsy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clin Infect Dis 2004;38:S409-413.
36. White BL, Wohl DA, Hays RD, et al. A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy. AIDS Patient Care STDs 2006;20:408-417.
37. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006;42:1619-1627.
38. McNell JI. A model for cultural competency in the HIV management of African American patients. J Natl Med Assoc 2003;95:S3-S7.